For this study, we described the main demographic and clinical characteristics of 3167 study participants who were at risk of hATTR amyloidosis, as part of the TRAMmoniTTR study, which included TTR genetic testing of this at-risk population. This evidence concerns the gene TTR and amyloidosis.